{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:56Z","timestamp":1772166596084,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871633"],"award-info":[{"award-number":["81871633"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["7181003"],"award-info":[{"award-number":["7181003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory state. Epstein\u2013Barr virus (EBV) infection-associated HLH (EBV-HLH) is one of the most common secondary HLH and suffers a very poor prognosis. Allo-HSCT is often required for refractory EBV-HLH, but some patients still cannot proceed to the next allo-HSCT due to various factors. This study aimed to observe the efficacy of HLA-mismatched granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (GPBSCs) infusion for refractory EBV-HLH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective case-control study of refractory EBV-HLH patients with GPBSC infusion from HLA-mismatched donors after chemotherapy (as GPBSC group) and sole chemotherapy (as control group) was performed. Efficacy was evaluated 2 and 4\u2009weeks and all patients were followed-up until March 1, 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 18 cases who accepted infusion between March 2016 and Sep 2017 and 19 were randomly selected from refractory EBV-HLH patients who underwent salvage therapy during the same period for the control group. In GPBSC group, WBC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), Fbg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040), and ferritin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039) improved significantly after treatment. The overall response rate was 66.7% (CR 22.2%, PR 44.4%). However, there are no significant differences in changes of WBC, HGB, PLT, TG, Fbg, Ferritin, AST, ALT, and T-bil between two groups. Only the Fbg level was recovered better in the GPBSC infusion group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). In the GPBSC group, EBV-DNA decreased significantly after 2\u2009weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and 4\u2009weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) after treatment, and the effect of the decrease was significantly better than that of the chemotherapy alone group in 2\u2009weeks but not 4\u2009weeks (p2w\u2009=\u20090.011, p4w\u2009=\u20090.145). The median survival time in the infusion group was 20.4\u2009weeks [95% CI 10.9, 29.9], and the median survival time in the control group was 10.8\u2009weeks [95% CI 0\u201324.34]. In the short-term, the infusion group\u2019s survival rate was better (2-month 88.89% vs. 52.63%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008; 3-month 83.33% vs. 47.09%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012), but there was no difference in OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.287).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Infusing GPBSCs combined with chemotherapy is effective, especially in decreasing EBV-DNA, performs better than chemotherapy alone, and improves short-term survival rate. GPBSC infusion is suggested as a bridging treatment method to allo-HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-020-01779-4","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T03:53:05Z","timestamp":1593575585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center"],"prefix":"10.1186","volume":"11","author":[{"given":"Yue","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yini","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"1779_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331.","journal-title":"Pediatr Blood Cancer"},{"key":"1779_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/rmv.638","volume":"20","author":"NR Maakaroun","year":"2010","unstructured":"Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20:93\u2013105.","journal-title":"Rev Med Virol"},{"key":"1779_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MPH.0b013e3181f84a52","volume":"33","author":"S Imashuku","year":"2011","unstructured":"Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011;33:35\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1779_CR4","doi-asserted-by":"publisher","first-page":"e11579","DOI":"10.1097\/MD.0000000000011579","volume":"97","author":"SA Merrill","year":"2018","unstructured":"Merrill SA, Naik R, Streiff MB, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine (Baltimore). 2018;97:e11579.","journal-title":"Medicine (Baltimore)"},{"key":"1779_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10245332.2018.1491093","volume":"23","author":"W Lai","year":"2018","unstructured":"Lai W, Wang Y, Wang J, Wu L, Jin Z, Wang Z. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents\u2014a life-threatening disease: analysis of 133 cases from a single center. Hematology. 2018;23:810\u20136.","journal-title":"Hematology"},{"key":"1779_CR6","first-page":"507","volume":"36","author":"X Zeng","year":"2015","unstructured":"Zeng X, Wei N, Wang Y, et al. Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Zhonghua Xue Ye Xue Za Zhi. 2015;36:507\u201310.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1779_CR7","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367\u201373.","journal-title":"Blood"},{"issue":"19","key":"1779_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","volume":"126","author":"YHW Wang","year":"2015","unstructured":"Wang YHW, Hu L, Cen X, Li L, Wang J. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186\u201392.","journal-title":"Blood"},{"key":"1779_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-016-0317-7","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016;9:84.","journal-title":"J Hematol Oncol"},{"key":"1779_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/10428194.2017.1330467","volume":"59","author":"Z Li","year":"2018","unstructured":"Li Z, Wang Y, Wang J, Zhang J, Wang Z. Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2018;59:77\u201384.","journal-title":"Leuk Lymphoma"},{"key":"1779_CR11","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1200\/JCO.2012.42.0281","volume":"30","author":"M Guo","year":"2012","unstructured":"Guo M, Hu KX, Liu GX, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol. 2012;30:4084\u201390.","journal-title":"J Clin Oncol"},{"key":"1779_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2017.2656","volume":"4","author":"M Guo","year":"2018","unstructured":"Guo M, Chao NJ, Li JY, et al. HLA-mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia: results from the microtransplantation interest group. JAMA Oncol. 2018;4:54\u201362.","journal-title":"JAMA Oncol"},{"key":"1779_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","volume":"117","author":"M Guo","year":"2011","unstructured":"Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011;117:936\u201341.","journal-title":"Blood"},{"key":"1779_CR14","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1080\/10428194.2017.1390235","volume":"59","author":"WY Li","year":"2018","unstructured":"Li WY, Wang Y, Chen SN, et al. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission. Leuk Lymphoma. 2018;59:1652\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1779_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/trf.12215","volume":"54","author":"L Yuan","year":"2014","unstructured":"Yuan L, Sun L, Yang L, Jing Y. Acute graft-versus-host disease in a nonhematopoietic stem cell transplantation candidate treated with decitabine followed by granulocyte colony-stimulating factor-primed peripheral blood stem cells infusion: a special entity of the disease? Transfusion. 2014;54:190\u20133.","journal-title":"Transfusion"},{"key":"1779_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pbc.24188","volume":"60","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60:101\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"1779_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jmii.2011.01.027","volume":"44","author":"YT Tseng","year":"2011","unstructured":"Tseng YT, Sheng WH, Lin BH, et al. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytic lymphohistiocytosis in Taiwanese adults. J Microbiol Immunol Infect. 2011;44:191\u20137.","journal-title":"J Microbiol Immunol Infect"},{"key":"1779_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12185-018-02572-z","volume":"109","author":"R Yanagisawa","year":"2019","unstructured":"Yanagisawa R, Nakazawa Y, Matsuda K, et al. Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan. Int J Hematol. 2019;109:206\u201313.","journal-title":"Int J Hematol"},{"key":"1779_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","volume":"2013","author":"GE Janka","year":"2013","unstructured":"Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematol Am Soc Hematol Educ Program. 2013;2013:605\u201311.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1779_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/pbc.22310","volume":"54","author":"S Ohga","year":"2010","unstructured":"Ohga S, Kudo K, Ishii E, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010;54:299\u2013306.","journal-title":"Pediatr Blood Cancer"},{"key":"1779_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","volume":"48","author":"G Orti","year":"2017","unstructured":"Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect. Exp Hematol. 2017;48:1\u201311.","journal-title":"Exp Hematol"},{"key":"1779_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MOH.0000000000000302","volume":"24","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wang Z. Treatment of hemophagocytic lymphohistiocytosis. Curr Opin Hematol. 2017;24:54\u20138.","journal-title":"Curr Opin Hematol"},{"key":"1779_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bbmt.2014.10.010","volume":"21","author":"HL Haines","year":"2015","unstructured":"Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015;21:288\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1779_CR24","first-page":"5738","volume":"7","author":"MC Smith","year":"2014","unstructured":"Smith MC, Cohen DN, Greig B, et al. The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder. Int J Clin Exp Pathol. 2014;7:5738\u201349.","journal-title":"Int J Clin Exp Pathol"},{"key":"1779_CR25","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1182\/blood.V96.8.2814","volume":"96","author":"NA Marshall","year":"2000","unstructured":"Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood. 2000;96:2814\u201321.","journal-title":"Blood"},{"key":"1779_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/bmt.2014.227","volume":"50","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Dignan FL, Tulpule S, et al. A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant. 2015;50:62\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1779_CR27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pbc.24980","volume":"61","author":"K Kogawa","year":"2014","unstructured":"Kogawa K, Sato H, Asano T, et al. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer. 2014;61:1257\u201362.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-020-01779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-020-01779-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-020-01779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T21:07:14Z","timestamp":1625087234000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-020-01779-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1186\/s13287-020-01779-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22776\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22776\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22776\/v1","asserted-by":"object"}]},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"2 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee at Beijing Friendship Hospital. Written informed consent was obtained from each patient and their family or guardian before the treatment began.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained consent to publish from the participants and\/or their families or guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}